• Explore /
  • Poster
  • / Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.

Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.

Abstract Poster

Authors

null

Christine Mateus

Gustave Roussy Institute, Villejuif, France

Christine Mateus , Emilie Routier , Severine Roy , Marina Thomas , Lise Boussemart , Isabelle Girault , Nathalie Chaput-Gras , Stephan Vagner , Hugo Cazenave , Lindi D Dalland , Mike R Lau , Maureen R Bleam , Anthony Michael D'amelio Jr., Sylvie Pfersch , Caroline Caty , Caroline Robert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Melanoma/Skin Cancers

Clinical Trial Registration Number

EudraCT number 2012-004577-12

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9114^)

DOI

10.1200/jco.2014.32.15_suppl.tps9114

Abstract #

TPS9114^

Poster Bd #

312A

Abstract Disclosures

Similar Posters

First Author: Michael S. Gordon

First Author: Jonathan S. Cebon

First Author: Jennifer Ann Wargo

First Author: Ryan Bruce Corcoran